Last reviewed · How we verify
Intramuscular midazolam
Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, producing sedation, anxiolysis, and muscle relaxation.
Midazolam is a benzodiazepine that enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, producing sedation, anxiolysis, and muscle relaxation. Used for Acute anxiety and agitation, Preoperative sedation and anxiolysis, Acute seizure management.
At a glance
| Generic name | Intramuscular midazolam |
|---|---|
| Sponsor | Hamad Medical Corporation |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Midazolam binds to GABA-A receptors and potentiates the effect of the inhibitory neurotransmitter GABA, leading to increased chloride ion influx and neuronal hyperpolarization. This results in depression of the central nervous system with sedative, anxiolytic, anticonvulsant, and muscle relaxant properties. When administered intramuscularly, it provides rapid onset of action suitable for acute sedation and anxiety management.
Approved indications
- Acute anxiety and agitation
- Preoperative sedation and anxiolysis
- Acute seizure management
- Sedation in critical care settings
Common side effects
- Drowsiness and sedation
- Dizziness
- Headache
- Respiratory depression
- Hypotension
- Injection site reactions
Key clinical trials
- Pediatric Dose Optimization for Seizures in Emergency Medical Services (PHASE3)
- Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK) (PHASE2, PHASE3)
- Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder (PHASE1, PHASE2)
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (PHASE1)
- Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability (PHASE4)
- AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine (PHASE3)
- Intramuscular Midazolam Versus Intravenous Diazepam for Acute Seizure in Children (EARLY_PHASE1)
- Intranasal vs Buccal vs Intramuscular Midazolam for the Home and Emergency Treatment of Acute Seizures (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intramuscular midazolam CI brief — competitive landscape report
- Intramuscular midazolam updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI